Hepatomegaly

11 registered clinical trials studyying Hepatomegaly — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly NCT07068191	Phenomen Pharma	N/A
Recruiting	Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders NCT03801434	William Shomali	Phase 2
Unknown	Prevalence of Hepatomegaly in Children and Adolescents With Type 1 Diabetes Mellitus NCT03666117	Assiut University	—
Withdrawn	Biomarker for Farber Disease (BioFarber) NCT02298634	CENTOGENE GmbH Rostock	—
Withdrawn	Biomarker for Sly Disease (MPS VII) (BioSly) NCT02298699	CENTOGENE GmbH Rostock	—
Withdrawn	Biomarker for Gaucher Disease: BioGaucher (BioGaucher) NCT01331642	CENTOGENE GmbH Rostock	—
Completed	S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis NCT03499808	SWOG Cancer Research Network	Phase 2
Terminated	Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Po NCT02421354	M.D. Anderson Cancer Center	Phase 2
Unknown	Open-Label Extension of LOCKCYST Trial NCT00771888	Radboud University Medical Center	Phase 2 / Phase 3
Completed	Lanreotide as Treatment of Polycystic Livers NCT00565097	Radboud University Medical Center	Phase 2 / Phase 3
Completed	Octreotide in Severe Polycystic Liver Disease NCT00426153	Mayo Clinic	Phase 2 / Phase 3